Abivax SA (FR:ABVX) has released an update.
Abivax SA, a biotech company, is on track with its Phase 3 ABTECT trial for obefazimod in treating ulcerative colitis, with enrollment completion expected in early Q1 2025 and top-line results due in early Q2 2025. The company has made significant advancements in its pre-clinical combination therapy program and financials, ensuring a cash runway into Q4 2025. Leadership changes include Sylvie Grégoire as new Board Chair and the appointment of Dr. Fabio Cataldi and Dr. David Zhang as Chief Medical Officer and Chief Strategy Officer, respectively.
For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.
